Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Eye Institute (R21EY025074)
Canada Research Chairs
Article History
Received: 18 February 2019
Accepted: 17 April 2019
First Online: 30 April 2019
Change Date: 10 March 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing Interests
: R.G.C. and P.M. declare no competing interestes. L.A.L. has served as a consultant on neuroprotection for the following pharmaceutical companies: Aerie, Allergan, Eyevensys, Galimedix, Prilenia, Quark, and Regenera.